Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 520 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Liver Transplant Clear all
Completed No phase listed Observational Accepts healthy volunteers

Rotational Thromboelastometry (ROTEM) TRUE-NATEM Reference Value Validation in Liver Transplantation

NCT04282889
View directory record Official record
Conditions
Coagulation in Liver Transplantation
Interventions
Not listed
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Sep 2, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

NCT00538850
View directory record Official record
Conditions
Cancer
Interventions
Fentanyl sublingual spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chandler, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Sep 2, 2026, 5:35 PM EDT
Active, not recruiting No phase listed Observational

Disparities Among Liver Transplant Patients

NCT05981196
View directory record Official record
Conditions
End Stage Liver DIsease
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Timeline
2023 – 2026
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 2, 2026, 5:35 PM EDT
Completed No phase listed Observational

Serum Markers of Ischemia Reperfusion Injury in Liver Transplant Patients

NCT00698399
View directory record Official record
Conditions
Liver Transplant
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Sep 2, 2026, 5:35 PM EDT
Recruiting Not applicable Interventional

HEalth Advocate for Liver Transplantation: Improving Transition of Care for Adolescent Liver Transplant Recipients

NCT06386198
View directory record Official record
Conditions
Liver Transplant; Complications
Interventions
Health Advocate
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 25 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
2
States / cities
San Francisco, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 2, 2026, 5:35 PM EDT
Active, not recruiting No phase listed Observational

The Effect of the COVID-19 Pandemic on Frailty in Liver Transplant Candidates

NCT05935800
View directory record Official record
Conditions
Frailty, Sarcopenia, COVID-19
Interventions
COVID Patients who Underwent pre-transplant frailty assessment (PFA) at MDMC
Behavioral
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 2, 2026, 5:35 PM EDT
Completed No phase listed Observational

Prevention of Recurrent Hepatitis B After Liver Transplantation

NCT00059267
View directory record Official record
Conditions
Hepatitis B, Cirrhosis, Acute Liver Failure, Hepatocellular Carcinoma
Interventions
HBIG, Epivir, Hepsera
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
13 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Sep 2, 2026, 5:35 PM EDT
Completed Phase 4 Interventional Results available

Impact of Everolimus on HIV Persistence Post Kidney or Liver Transplant

NCT02429869
View directory record Official record
Conditions
HIV, Kidney Transplant, Liver Transplant
Interventions
everolimus
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Sep 2, 2026, 5:35 PM EDT
Completed Phase 1 Interventional

High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer

NCT00002854
View directory record Official record
Conditions
Cancer
Interventions
filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, ifosfamide, mesna, paclitaxel, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2015
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Sep 2, 2026, 5:35 PM EDT
Terminated Not applicable Interventional Results available

OCS Liver DCD Trial

NCT04194437
View directory record Official record
Conditions
Liver Transplant
Interventions
OCS Liver System
Device
Lead sponsor
TransMedics
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Boston, Massachusetts • Detroit, Michigan • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 2, 2026, 5:35 PM EDT
Terminated No phase listed Observational

Genetic Studies of Non-Alcoholic Fatty Liver Disease

NCT01629095
View directory record Official record
Conditions
Non-Alcoholic Steato-Hepatitis, Liver Cirrhosis, Non-Alcoholic Fatty Liver Disease
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
1 Month and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
San Francisco, California • Bethesda, Maryland • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2020 · Synced Sep 2, 2026, 5:35 PM EDT
Terminated Phase 2 Interventional

B-Lymphocyte Immunotherapy in Islet Transplantation

NCT00468442
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Allogeneic Pancreatic Islet Cells, Antithymocyte globulin, Daclizumab, Rituximab, Sirolimus
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 20, 2016 · Synced Sep 2, 2026, 5:35 PM EDT
Terminated Not applicable Interventional Results available

Polycystic Liver Disease in Kidney Transplant

NCT00934791
View directory record Official record
Conditions
Polycystic Liver Disease
Interventions
Tacrolimus, Sirolimus, Mycophenolate Mofetil, Prednisone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Sep 2, 2026, 5:35 PM EDT
Completed Not applicable Interventional

Acute Renal Failure Post Liver Transplantation

NCT01907061
View directory record Official record
Conditions
Acute Renal Failure
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 71 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Sep 2, 2026, 5:35 PM EDT
Completed No phase listed Observational

Cefepime Pharmacokinetics in Liver Transplant Recipients in an Intensive Care Unit

NCT00177931
View directory record Official record
Conditions
Evidence of Liver Transplantation
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 16, 2015 · Synced Sep 2, 2026, 5:35 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Immune Monitoring and Assay Development in Organ Transplant Recipients

NCT01283295
View directory record Official record
Conditions
Organ Transplantation, Transplantation Immunology
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Sep 2, 2026, 5:35 PM EDT
Recruiting Not applicable Interventional

Alcohol Treatment Outcomes Following Early vs. Standard Liver Transplant for SAH

NCT03845205
View directory record Official record
Conditions
Alcohol Use Disorder, Alcoholic Hepatitis
Interventions
Integrated AUD Treatment
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 2, 2026, 5:35 PM EDT
Recruiting Phase 2 Interventional

Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

NCT07335601
View directory record Official record
Conditions
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions
Resmetirom, Placebo
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
16
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 2, 2026, 5:35 PM EDT
Recruiting Phase 1Phase 2 Interventional

Improving Islet Transplantation Outcomes With Gastrin for Type I Diabetes

NCT03746769
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Allogenic Human Islet Cells, Gastrin 17
Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 68 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 2, 2026, 5:35 PM EDT
Completed Phase 4 Interventional Results available

Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C

NCT00938860
View directory record Official record
Conditions
Hepatitis C, Liver Transplantation
Interventions
cyclosporin (Neoral), tacrolimus (Prograf)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
9
States / cities
Phoenix, Arizona • Palo Alto, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Sep 2, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics of LCP-Tacro™ Once Daily and Prograf® Twice A Day in Adult De Novo Liver Transplant Patients

NCT00772148
View directory record Official record
Conditions
Liver Failure
Interventions
LCP -Tacro, Prograf
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Sep 2, 2026, 5:35 PM EDT
Terminated No phase listed Observational

Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Cirrhotics

NCT00375011
View directory record Official record
Conditions
Cirrhosis
Interventions
Not listed
Lead sponsor
Meridian Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Sep 2, 2026, 5:35 PM EDT
Terminated Phase 2 Interventional Results available

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension

NCT03781414
View directory record Official record
Conditions
Liver Transplant Rejection
Interventions
CFZ533, Tacrolimus - MMF - corticosteroids
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
9
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 2, 2026, 5:35 PM EDT
Completed No phase listed Observational

Prospective Study of Drug Resistant Pathogens Among Liver, Intestinal and Multivisceral Transplant Recipients

NCT00235664
View directory record Official record
Conditions
Transplantation
Interventions
Collection of stool and endotracheal aspirate samples
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 16, 2008 · Synced Sep 2, 2026, 5:35 PM EDT